Sugi Predict

Sugi Predict / Targets / CCNA2

CCNA2

Cyclin-A2 · P20248 · CCNA2 on Sugi Atlas →

183,815 patent compounds predicted against CCNA2, 109,071 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL21169 SCHEMBL21169 0.55 19/20
SCHEMBL20693 SCHEMBL20693 0.53 19/20
SCHEMBL19015 SCHEMBL19015 0.51 19/20
SCHEMBL214000 SCHEMBL214000 0.61 18/20
SCHEMBL31357 SCHEMBL31357 0.50 18/20
SCHEMBL31358 SCHEMBL31358 0.50 18/20
SCHEMBL214742 SCHEMBL214742 0.52 17/20
Methylguanine Methylguanine (SCHEMBL34851) 0.51 16/20
Methylguanine Methylguanine (SCHEMBL231097) 0.69 14/20
Purvalanol B Purvalanol B (SCHEMBL27951) 1.00 13/20
SCHEMBL102235 SCHEMBL102235 0.79 12/20
SCHEMBL102656 SCHEMBL102656 0.79 12/20
SCHEMBL102951 SCHEMBL102951 0.76 12/20
SCHEMBL102660 SCHEMBL102660 0.75 12/20
Tetrabuthylammonium Tetrabuthylammonium (SCHEMBL200612) 0.58 12/20
SCHEMBL102233 SCHEMBL102233 1.00 11/20
SCHEMBL102955 SCHEMBL102955 1.00 11/20
SCHEMBL103266 SCHEMBL103266 0.82 11/20
SCHEMBL102650 SCHEMBL102650 0.76 11/20
SCHEMBL190547 SCHEMBL190547 0.61 11/20

Clinical trials — most relevant to CCNA2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt PHASE4COMPLETED
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas PHASE2RECRUITING
Cyclin D1 Based TPF Induction Chemotherapy for Oral Squamous Cell Carcinoma Patients at Clinical N2 Stage PHASE2RECRUITING
Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer PHASE2RECRUITING
Bryostatin 1 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer PHASE2COMPLETED
Abemaciclib With or Without Atezolizumab for mCRPC PHASE2COMPLETED
Histology-Independent Study of Palbociclib in Patients With Advanced Cancer PHASE2WITHDRAWN
Bortezomib in Treating Patients With Advanced or Metastatic Sarcoma PHASE2COMPLETED
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6 PHASE2RECRUITING
Everolimus in CDK12-Deficient Metastatic Colorectal Cancer (EVER-RECODE) PHASE1/PHASE2NOT_YET_RECRUITING
Abemaciclib + Pembrolizumab In Glioblastoma PHASE2WITHDRAWN
Efficacy Study Of P276-00 In Subjects Of Malignant Melanoma Positive For Cyclin D1 Expression PHASE2COMPLETED
Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC) PHASE1/PHASE2RECRUITING
CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer PHASE2ACTIVE_NOT_RECRUITING
LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE) PHASE2COMPLETED
ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas PHASE1/PHASE2COMPLETED
TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer PHASE2UNKNOWN
A Study of Abemaciclib in Recurrent Glioblastoma PHASE2ACTIVE_NOT_RECRUITING
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors PHASE1RECRUITING
Clinical Study of Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) PHASE1SUSPENDED
Phase I Study for Safety and Efficacy of P276-00 in Subjects With Myeloma PHASE1WITHDRAWN
Erlotinib in Treating Patients With Barrett Esophagus PHASE1UNKNOWN
A Pharmacologic Study of CYC065, a Cyclin Dependent Kinase Inhibitor, in Patients With Advanced Cancers PHASE1COMPLETED
AZD1775 for Advanced Solid Tumors PHASE1COMPLETED
Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma PHASE1COMPLETED
Open Label Phase I Study of P276-00 in Patients With Advanced Refractory Neoplasms PHASE1COMPLETED
Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies PHASE1RECRUITING
the Efficacy and Safety of Dalpiciclib Combined With Third-generation EGFR-TKI in Patients With EGFR Mutation and Meningial Metastasis in Non-small Cell Lung Cancer Progressing Through Third-generation TKI and Platinum-containing Two-drug Chemotherapy nanUNKNOWN
Prevalence of Dysplasia of the Gastric Cardia nanCOMPLETED
Genetic Analysis of Familial Melanoma nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a CCNA2 binder may also engage these)

ProteinNameSimilarity
P51943 — 1.000 P51943 →
P04962 — 1.000 P04962 →
P47827 — 1.000 P47827 →
P30274 — 1.000 P30274 →
Q0D9C7 — 1.000 Q0D9C7 →
A2YH60 — 1.000 A2YH60 →
Q39070 — 0.999 Q39070 →
Q9C968 — 0.998 Q9C968 →
Q61456 — 0.998 Q61456 →
Q38819 — 0.998 Q38819 →
Q92161 — 0.998 Q92161 →
P46278 — 0.997 P46278 →
Q3ECW2 — 0.997 Q3ECW2 →
Q6AY13 — 0.997 Q6AY13 →
P37881 — 0.997 P37881 →
Q9LDM4 — 0.996 Q9LDM4 →
P18606 — 0.996 P18606 →
Q7F830 — 0.996 Q7F830 →
Q0INT0 — 0.996 Q0INT0 →
Q0JIF2 — 0.996 Q0JIF2 →
Q0DH40 — 0.996 Q0DH40 →
Q9C6Y3 — 0.996 Q9C6Y3 →
Q147G5 — 0.995 Q147G5 →
P34800 — 0.995 P34800 →
P25011 — 0.995 P25011 →
Q01J96 — 0.995 Q01J96 →
Q7XSJ6 — 0.995 Q7XSJ6 →
P36630 — 0.995 P36630 →
Q39069 — 0.994 Q39069 →
Q0JPA4 — 0.994 Q0JPA4 →